Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12 June 2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started a Phase III clinical trial with a three-month formulation of Invega Sustenna (paliperidone palmitate) for schizophrenia.

This will be the first-ever three-month atypical medication in development for schizophrenia. It expands the J&J/ALKS franchise of long-acting drugs for schizophrenia, currently with more than $2 billion in annual product sales, with approved products Invega Sustenna (1-month administration) and Risperdal Consta (risperidone; once every 2 week administration) – both long-acting injectable medications for atypical antipsychotic daily pills. Invega Sustenna generated sales of $499 million in the first quarter of 2012.

Two Phase III studies are expected to enroll around 1,800 patients with schizophrenia and will assess the efficacy, safety and tolerability of the three-month injectable formulation. These studies are expected to be completed in the second half of calendar 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK